Description
Details
Gen 1 Cardiomyocytes are derived from NIH Registered human Embryonic Stem Cells (hESC) and provide a biologically-relevant model for use in safety screening and risk assessment of compounds for cardiotoxic responses in drug discovery. Suitable for interrogation in multiparametic platforms such as high-content analysis (HCA) and multielectrode arrays (MEA), Gen 1 Cardiomyocytes form spontaneously beating monolayers when plated into microwell plates and exhibit appropriate morphology and electrophysiological responses when treated with known compounds.
Gen 1 Cardiomyocytes have been extensively characterized and functionally verified by flow cytometry, sub-cellular imaging and electrophysiology. Cells are provided cryopreserved in a ready-to-use format.
Gen 1 Cardiomyocytes have been extensively characterized and functionally verified by flow cytometry, sub-cellular imaging and electrophysiology. Cells are provided cryopreserved in a ready-to-use format.
Details
Details
| Format | Frozen in 1.0 mL cryovials containing 10% DMSO and 90% fetal bovine serum |
|---|---|
| Size | 1.0X10^⁶ viable cells |
| Storage | Liquid nitrogen; vapor phase |
| Expiration | Refer to the appropriate certificate of analysis |
| Stem Cell Source | Cell Line WA07 (H7); NIH Approval # NIHhESC-10-0061 |
| Characterization | Flow cytometry; sub-cellular imaging; electrophysiology |
| Technical Documents | Cytiva Plus User’s Manual |
| Legal | Gen 1 Cardiomyocytes are provided under license from GE Healthcare, UK Limited. |